Biopharma Daily Stock Updates - 01/27/21

$XBI $152.30 (-1.35%) 📉

COVID:

$BNTX (-0.30%) & $PFE (-2.87%) - In Vitro Studies Demonstrate Pfizer and BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with Key Mutations Present in U.K. and South African Variants

$ONCS (-2.64%) - OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12, OncoSec's COVID-19 Vaccine Candidate Combining Interleukin-12 (IL-12) with an Enhanced SARS-CoV-2 Spike Protein

$MRNA (+2.50%) - Moderna Confirms Discussions with U.S. Government for Additional 100 Million Doses of the Moderna COVID-19 Vaccine

$SRNE (+46.16%) - Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients

$HGEN (+0.37%) - Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study

PIPELINE:

$GBT (+6.97%) - European Medicines Agency Accepts GBT’s Marketing Authorization Application (MAA) for Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Sickle Cell Disease

$ZYME (-4.78%) - Zymeworks Advances HER2 Bispecific Antibody-Drug Conjugate, ZW49, into Expansion Cohort Stage of Clinical Development

$AGTC (-5.72%) - AGTC Announces First Reported Improvements in Visual Sensitivity for Achromatopsia (ACHM) patients from its Ongoing Clinical Trials

FINANCIAL:

$AGTC (-5.72%) - AGTC Announces Proposed Public Offering of Common Stock and Warrants

$CBIO (-9.16%) - Catalyst Biosciences Announces Pricing of Public Offering of Common Stock